DE SANTIS, SARA
 Distribuzione geografica
Continente #
NA - Nord America 401
EU - Europa 305
AS - Asia 82
AF - Africa 46
SA - Sud America 3
Totale 837
Nazione #
US - Stati Uniti d'America 399
IT - Italia 112
SE - Svezia 49
GB - Regno Unito 43
DE - Germania 35
IE - Irlanda 35
SG - Singapore 32
TG - Togo 29
IN - India 22
CN - Cina 14
NG - Nigeria 10
JO - Giordania 8
CH - Svizzera 5
FR - Francia 5
BG - Bulgaria 4
CI - Costa d'Avorio 4
PL - Polonia 4
RU - Federazione Russa 4
FI - Finlandia 3
ZA - Sudafrica 3
CA - Canada 2
DK - Danimarca 2
EC - Ecuador 2
EE - Estonia 2
TR - Turchia 2
UA - Ucraina 2
CL - Cile 1
HK - Hong Kong 1
IQ - Iraq 1
IR - Iran 1
KR - Corea 1
Totale 837
Città #
Chandler 100
Southend 40
Dublin 35
Bologna 31
Lomé 29
Singapore 26
Fairfield 20
Princeton 20
Redmond 20
Ashburn 13
Wilmington 12
Abeokuta 10
Woodbridge 10
Berlin 9
Houston 9
Turin 9
Amman 8
Cambridge 7
Seattle 7
Florence 6
New York 6
San Diego 6
Bern 5
Boydton 5
Milan 5
Rome 5
Santa Clara 5
Abidjan 4
Ann Arbor 4
Dehradun 4
Des Moines 4
Sofia 4
Warsaw 4
Beijing 3
Bremen 3
Brescia 3
Castel Madama 3
Catania 3
Medford 3
Modena 3
Saint Petersburg 3
Shenyang 3
Westminster 3
Zhengzhou 3
Ankara 2
Bochum 2
Cervia 2
Fano 2
Francofonte 2
Frederiksberg 2
Grand Forks 2
Guayaquil 2
Helsinki 2
Imola 2
Latina 2
Malvern 2
Miradolo Terme 2
Mountain View 2
Mumbai 2
Norwalk 2
Noventa Vicentina 2
Olalla 2
Padova 2
Siena 2
Toronto 2
Trecate 2
Venice 2
Bangalore 1
Bühl 1
Canzo 1
Cesena 1
Fremont 1
Hebei 1
Lanzhou 1
Lappeenranta 1
Lissone 1
London 1
Los Angeles 1
Mannheim 1
Nanchang 1
Nanjing 1
North Bergen 1
Reggio Emilia 1
Rostock 1
San Francisco 1
Seoul 1
Tianjin 1
Totale 581
Nome #
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 121
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 102
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 89
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 74
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 72
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 71
The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities 67
Recent advances in the molecular biology of systemic mastocytosis: Implications for diagnosis, prognosis, and therapy 64
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia 44
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 40
Targeting leukemic stem cells in chronic myeloid leukemia: Is it worth the effort? 39
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 28
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors 23
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 21
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 14
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 12
Totale 881
Categoria #
all - tutte 3.384
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.384


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202044 0 3 0 3 7 3 7 4 5 4 4 4
2020/202172 7 2 0 0 1 2 9 21 9 3 7 11
2021/2022172 3 0 5 4 20 12 2 15 11 15 50 35
2022/2023376 42 62 9 31 39 21 19 15 71 13 42 12
2023/2024132 1 25 13 20 12 13 5 17 3 9 11 3
2024/202557 23 34 0 0 0 0 0 0 0 0 0 0
Totale 881